Segui
Daniele Lavacchi
Daniele Lavacchi
Clinical Oncology Unit, Careggi University Hospital, Florence, Italy
Email verificata su aou-careggi.toscana.it
Titolo
Citata da
Citata da
Anno
MSI and EBV positive gastric cancer’s subgroups and their link with novel immunotherapy
MG Rodriquenz, G Roviello, A D’Angelo, D Lavacchi, F Roviello, K Polom
Journal of clinical medicine 9 (5), 1427, 2020
682020
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
D Lavacchi, F Mazzoni, G Giaccone
Drug design, development and therapy, 3187-3198, 2019
492019
Immune checkpoint inhibitors in the treatment of renal cancer: current state and future perspective
D Lavacchi, E Pellegrini, VE Palmieri, L Doni, MM Mela, F Di Maida, ...
International journal of molecular sciences 21 (13), 4691, 2020
442020
Tumor-agnostic treatment for cancer: when how is better than where
D Lavacchi, G Roviello, A D’Angelo
Clinical drug investigation 40, 519-527, 2020
422020
Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer
G Roviello, A D'Angelo, R Petrioli, F Roviello, F Cianchi, S Nobili, E Mini, ...
Translational Oncology 13 (9), 100795, 2020
342020
Results of the observational prospective RealFLOT study
E Giommoni, D Lavacchi, G Tirino, L Fornaro, F Iachetta, C Pozzo, ...
BMC cancer 21, 1-11, 2021
242021
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: a real-world analysis
A Paderi, E Gambale, C Botteri, R Giorgione, D Lavacchi, M Brugia, ...
Molecules 26 (19), 5789, 2021
242021
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer
G Roviello, FU Conter, E Mini, D Generali, M Traversini, D Lavacchi, ...
Cancer chemotherapy and pharmacology 84, 669-677, 2019
202019
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
M Rimini, L Fornaro, S Lonardi, M Niger, D Lavacchi, T Pressiani, ...
Liver International 43 (8), 1803-1812, 2023
192023
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer
G Randon, R Intini, C Cremolini, E Elez, MJ Overman, J Lee, P Manca, ...
European Journal of Cancer 161, 90-98, 2022
152022
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: the multicenter retrospective CLARITY study
M Bersanelli, S Buti, D Giannarelli, A Leonetti, A Cortellini, GL Russo, ...
Lung Cancer 150, 123-131, 2020
152020
Electronic nicotine delivery systems (ENDS): not still ready to put on END
D Lavacchi, G Roviello, MG Rodriquenz
Journal of thoracic disease 12 (7), 3857, 2020
132020
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
D Ciardiello, C Chiarazzo, V Famiglietti, A Damato, C Pinto, MG Zampino, ...
ESMO open 7 (5), 100567, 2022
112022
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy
E Caliman, S Fancelli, C Ottanelli, F Mazzoni, L Paglialunga, D Lavacchi, ...
Cancer Treatment and Research Communications 32, 100603, 2022
102022
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy …
E Lastraioli, L Antonuzzo, B Fantechi, L Di Cerbo, A Di Costanzo, ...
Oncology Letters 21 (1), 1-1, 2021
102021
Perioperative tailored treatments for gastric cancer: times are changing
D Lavacchi, S Fancelli, E Buttitta, G Vannini, A Guidolin, C Winchler, ...
International Journal of Molecular Sciences 24 (5), 4877, 2023
92023
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
D Lavacchi, S Fancelli, G Roviello, F Castiglione, E Caliman, G Rossi, ...
Frontiers in Oncology 12, 1055019, 2022
92022
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience
C Bardasi, A Spallanzani, S Benatti, F Spada, A Laffi, L Antonuzzo, ...
Endocrine 74, 707-713, 2021
92021
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination
G Roviello, S Fancelli, MRG Michelet, G Aprile, S Nobili, F Roviello, ...
Critical Reviews in Oncology/Hematology 152, 102987, 2020
92020
Vinorelbine in non-small cell lung cancer: real-world data from a single-institution experience
S Nobili, D Lavacchi, G Perrone, G Vicini, R Tassi, I Landini, AM Grosso, ...
Oncology Research 28 (3), 237, 2020
92020
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20